Tag: action

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the “Class Period”), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc., No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat and certain of Red Cat’s top current and former executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ibotta, Inc. (NYSE: IBTA) publicly traded securities pursuant and/or traceable to Ibotta’s registration statement and related prospectus issued in connection with Ibotta’s initial public offering (the “IPO”) held on or around April 18, 2024, have until Monday, June 16, 2025 to seek appointment as lead plaintiff of the Ibotta class action lawsuit. Captioned Fortune v. Ibotta, Inc., No. 25-cv-01213 (D. Colo.), the Ibotta class action lawsuit charges Ibotta as well as certain of Ibotta’s top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933.

PRESS RELEASE

COMMUNIQUE DE PRESSE

Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (the “IPO”); or (2) between April 18, 2024 and February 26, 2025, inclusive (the “Class Period”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm.